NewGenIvf Group Stock to Reverse Split on Monday, March 16th (NASDAQ:NIVF)

NewGenIvf Group Limited (NASDAQ:NIVF)’s stock is set to reverse split on the morning of Monday, March 16th. The 1-4 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Sunday, March 15th.

NewGenIvf Group Stock Down 2.9%

NewGenIvf Group stock traded down $0.02 during trading hours on Thursday, hitting $0.50. The company had a trading volume of 47,689 shares, compared to its average volume of 118,640. The company has a debt-to-equity ratio of 0.17, a current ratio of 3.43 and a quick ratio of 3.37. NewGenIvf Group has a 1 year low of $0.48 and a 1 year high of $1,110.00. The company has a 50-day moving average price of $1.16 and a two-hundred day moving average price of $10.81.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on NIVF shares. Weiss Ratings reaffirmed a “sell (d)” rating on shares of NewGenIvf Group in a research report on Wednesday, January 28th. Wall Street Zen upgraded NewGenIvf Group to a “hold” rating in a report on Saturday, December 6th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, NewGenIvf Group currently has an average rating of “Sell”.

NewGenIvf Group Company Profile

NewGenIVF Group Inc, trading on NASDAQ under the symbol NIVF, is an integrated provider of reproductive medicine services in the People’s Republic of China. The company operates a network of fertility clinics across major Chinese cities, delivering comprehensive infertility diagnosis and treatment to patients and couples. Its facilities are equipped with modern laboratories and surgical suites designed for assisted reproductive procedures.

NewGenIVF’s service offerings encompass a wide range of assisted reproductive technologies (ART), including in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), preimplantation genetic testing (PGT), and fertility preservation through ovarian tissue and gamete cryopreservation.